Sayantee Hazra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sayantee Hazra has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Biswajit Biswas
Department of Bioscience and Biotechnology, Indian Institute of Technology Kharagpur , Kharagpur, West Bengal 721302
3 shared publications - Ritobrata Goswami
Department of Bioscience and Biotechnology, Indian Institute of Technology Kharagpur, West Bengal 721302, India
3 shared publications - Shagnik Chattopadhyay
Department of Bioscience and Biotechnology, Indian Institute of Technology Kharagpur , Kharagpur, West Bengal 721302
3 shared publications Arindam Mondal
Indian Institute of Technology Kharagpur
1 shared publicationSupratik Nandan
Indian Institute of Technology Kharagpur
1 shared publicationSwayam Prava Mansingh
Indian Institute of Technology Kharagpur
1 shared publication
Latest Publications
- 6 November 2025
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 117 (12)
HOXA9-PBX1 axis orchestrates divergent Th2 cytokine expression
Evolutionarily conserved HOXA9 is a well-known player of hematopoiesis and leukemogenesis. However, the involvement of this transcription factor in CD4+ T cell development is largely unexplored. Th2 cells play a critical role in the pathogenesis of numerous autoimmune disorders. The development of this heterogenic subpopulation of cells is orchestrated by a consortium of factors including GATA3 and PU.1, among others. Here, we recognized the molecular regulation bestowed by HOXA9 in Th2 cell development. We found that overexpression of HOXA9 in Th2 cell leads to increased secretion of IL-10 while suppressing IL-4 and IL-13. Through promoter activity analysis, we determined the crucial role played by the structural domains of HOXA9 on Th2-specific cytokines. These findings further indicated the presence of other cofactors that contribute to the functional activity of HOXA9. Our findings demonstrated that HOXA9 can engage in physical interactions with PU.1 and PBX1, but not with GATA3, and exhibits direct binding to PU.1-specific chromosomal loci within Th2 cells. PBX1 overexpression stimulates the secretion of IL-4, IL-13, and IL-10. In contrast, the combined overexpression of HOXA9 and PBX1 suppresses IL-4 and IL-13 secretion but boosts IL-10 production. Taken together, the data suggest that PBX1 acts specifically as a coregulator for HOXA9 in the context of Th2 cell function. The contribution of HOXA9 and PBX1 is significantly more pronounced in the proximal promoter region of the Il10 gene. This study has significantly advanced our understanding of Th2 cell differentiation and cytokine production, regulated by HOXA9-PBX1 axis through interactions with other key transcription factors.
- 6 November 2025
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 117 (12)
HOXA9-PBX1 axis orchestrates divergent Th2 cytokine expression
Evolutionarily conserved HOXA9 is a well-known player of hematopoiesis and leukemogenesis. However, the involvement of this transcription factor in CD4+ T cell development is largely unexplored. Th2 cells play a critical role in the pathogenesis of numerous autoimmune disorders. The development of this heterogenic subpopulation of cells is orchestrated by a consortium of factors including GATA3 and PU.1, among others. Here, we recognized the molecular regulation bestowed by HOXA9 in Th2 cell development. We found that overexpression of HOXA9 in Th2 cell leads to increased secretion of IL-10 while suppressing IL-4 and IL-13. Through promoter activity analysis, we determined the crucial role played by the structural domains of HOXA9 on Th2-specific cytokines. These findings further indicated the presence of other cofactors that contribute to the functional activity of HOXA9. Our findings demonstrated that HOXA9 can engage in physical interactions with PU.1 and PBX1, but not with GATA3, and exhibits direct binding to PU.1-specific chromosomal loci within Th2 cells. PBX1 overexpression stimulates the secretion of IL-4, IL-13, and IL-10. In contrast, the combined overexpression of HOXA9 and PBX1 suppresses IL-4 and IL-13 secretion but boosts IL-10 production. Taken together, the data suggest that PBX1 acts specifically as a coregulator for HOXA9 in the context of Th2 cell function. The contribution of HOXA9 and PBX1 is significantly more pronounced in the proximal promoter region of the Il10 gene. This study has significantly advanced our understanding of Th2 cell differentiation and cytokine production, regulated by HOXA9-PBX1 axis through interactions with other key transcription factors.
- Open Access
- 7 October 2024
- Published by Wiley
All-trans Retinoic Acid Suppresses IL-4 and IL-13 production in Th2 cells by modulating the nuclear receptor RARα, and Gfi1
All- trans retinoic acid (atRA), bioactive component of vitamin A, plays a pivotal role in various biological processes. Essential for embryonic development, bone growth and maintenance, and immune function, atRA exerts its regulatory effects primarily through its interaction with the nuclear receptor RARα. Upon binding to RARα, atRA enters the nucleus and forms a heterodimer with RXR. This heterodimer can then interact with various transcription factors to form regulatory complexes that influence gene expression. While the role of atRA in regulating the type 2 immune response has been studied, the role atRA in Th2 cell differentiation is warranted to fully elucidate its mechanisms and potential therapeutic applications. Our study shows that atRA suppressed Th2 phenotype by down-regulating type 2 transcription factors such as Spi1 and cMaf . atRA also down-regulated IL-4 and IL-13 production in Th2 cells, potentially by up-regulating Gfi1, a transcriptional repressor. atRA increased the Gfi1 recruitment to the Il4 and Il13 promoters, along with the common enhancer Ecr. RARα, which is typically an inducer of Il4 and Il13 , was observed to decrease recruitment to these loci in atRA-treated Th2 cells. Comparative gene expression analysis revealed a reduction in inflammatory responses in atRA-treated Th2 cells. Furthermore, these cells exhibited a negative correlation with epigenetic modifications, nuclear receptor activity among other biological processes. Collectively, our findings suggest that atRA can effectively suppress the Th2 phenotype in vitro, through the regulation of key type 2 transcription factors and associated biological pathways, indicating its potential therapeutic implications for limiting type 2 immune responses.
- 7 October 2024
- Published by Wiley
Open AccessAll-trans Retinoic Acid Suppresses IL-4 and IL-13 production in Th2 cells by modulating the nuclear receptor RARα, and Gfi1
All- trans retinoic acid (atRA), bioactive component of vitamin A, plays a pivotal role in various biological processes. Essential for embryonic development, bone growth and maintenance, and immune function, atRA exerts its regulatory effects primarily through its interaction with the nuclear receptor RARα. Upon binding to RARα, atRA enters the nucleus and forms a heterodimer with RXR. This heterodimer can then interact with various transcription factors to form regulatory complexes that influence gene expression. While the role of atRA in regulating the type 2 immune response has been studied, the role atRA in Th2 cell differentiation is warranted to fully elucidate its mechanisms and potential therapeutic applications. Our study shows that atRA suppressed Th2 phenotype by down-regulating type 2 transcription factors such as Spi1 and cMaf . atRA also down-regulated IL-4 and IL-13 production in Th2 cells, potentially by up-regulating Gfi1, a transcriptional repressor. atRA increased the Gfi1 recruitment to the Il4 and Il13 promoters, along with the common enhancer Ecr. RARα, which is typically an inducer of Il4 and Il13 , was observed to decrease recruitment to these loci in atRA-treated Th2 cells. Comparative gene expression analysis revealed a reduction in inflammatory responses in atRA-treated Th2 cells. Furthermore, these cells exhibited a negative correlation with epigenetic modifications, nuclear receptor activity among other biological processes. Collectively, our findings suggest that atRA can effectively suppress the Th2 phenotype in vitro, through the regulation of key type 2 transcription factors and associated biological pathways, indicating its potential therapeutic implications for limiting type 2 immune responses.
- Open Access
Calcitriol impairs the secretion of IL-4 and IL-13 in Th2 cells via modulating VDR-Gata3-Gfi1 axis
Calcitriol, the bioactive form of vitamin D, exerts its biological functions by binding to its cognate receptor VDR. The indicators of the severity of allergies and asthma have been linked to low vitamin D levels. However, the role of calcitriol in regulating IL-4 and IL-13; two cytokines pivotal to allergic inflammation, remained unclear. Our study observed a decrease in IL-4 and IL-13 secretion in murine and human Th2 cells, treated with calcitriol. In murine Th2 cells, Gata3 expression was attenuated by calcitriol. However, the expression of the transcriptional repressor Gfi1, that prevents Th1 fate of activated CD4+ T cells, too was attenuated in the presence of calcitriol. Ectopic expression of either Gfi1 or VDR impaired the secretion of IL-13 in Th2 cells. Gfi1 significantly impaired Il13 promoter activation; which calcitriol failed to restore. Ecr, a conserved region between the two genes, which enhanced the transactivation of Il4 and Il13 promoters; is essential for calcitriol-mediated suppression of both the genes. In murine Th2 cells, VDR interacted with Gata3 but not Gfi1. Calcitriol augmented the recruitment of VDR to the Il13 promoter and Ecr regions. Gata3 recruitment was significantly impaired at Il13 and Ecr locus in the presence of calcitriol but increased at Il4 promoter. However, in the presence of calcitriol, the overall recruitment of Gfi1 remained unchanged at Il4 but increased at Il13 locus in Th2 cells. Together, our study clearly elucidates that calcitriol modulates VDR, Gata3, and Gfi1 to suppress IL-4 and IL-13 production in Th2 cells. Abstract Figure:
Open AccessCalcitriol impairs the secretion of IL-4 and IL-13 in Th2 cells via modulating VDR-Gata3-Gfi1 axis
Calcitriol, the bioactive form of vitamin D, exerts its biological functions by binding to its cognate receptor VDR. The indicators of the severity of allergies and asthma have been linked to low vitamin D levels. However, the role of calcitriol in regulating IL-4 and IL-13; two cytokines pivotal to allergic inflammation, remained unclear. Our study observed a decrease in IL-4 and IL-13 secretion in murine and human Th2 cells, treated with calcitriol. In murine Th2 cells, Gata3 expression was attenuated by calcitriol. However, the expression of the transcriptional repressor Gfi1, that prevents Th1 fate of activated CD4+ T cells, too was attenuated in the presence of calcitriol. Ectopic expression of either Gfi1 or VDR impaired the secretion of IL-13 in Th2 cells. Gfi1 significantly impaired Il13 promoter activation; which calcitriol failed to restore. Ecr, a conserved region between the two genes, which enhanced the transactivation of Il4 and Il13 promoters; is essential for calcitriol-mediated suppression of both the genes. In murine Th2 cells, VDR interacted with Gata3 but not Gfi1. Calcitriol augmented the recruitment of VDR to the Il13 promoter and Ecr regions. Gata3 recruitment was significantly impaired at Il13 and Ecr locus in the presence of calcitriol but increased at Il4 promoter. However, in the presence of calcitriol, the overall recruitment of Gfi1 remained unchanged at Il4 but increased at Il13 locus in Th2 cells. Together, our study clearly elucidates that calcitriol modulates VDR, Gata3, and Gfi1 to suppress IL-4 and IL-13 production in Th2 cells. Abstract Figure: